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Abstract
Background: Phyllodes tumors are rare fibroepithelial tumors accounting for less than 1 % of all breast neoplasms.
They are malignant in 20 % of cases. Only a few cases of malignant phyllodes tumors metastatic to bone have
been reported.
Case presentation: Case 1: A 40 year-old white woman presented with three-week history of pain and functional
impairment of the left lower limb. Her clinical past was remarkable for previous left mastectomy and radiotherapy
for malignant phyllodes tumor performed one year ago. Computed tomography revealed a moth-eaten
appearance of the left femoral head. The patient underwent computed guided femoral head biopsy. Pathological
findings were consistent with metastatic malignant phyllodes tumor. The patient received ifosfamide and
adriamycin chemotherapy. She is doing well without any evidence of progression on her imaging follow- up after
8 months.
Case 2: A 48 year-old white woman, with history of bilateral mastectomy and radiotherapy for malignant phyllodes
tumor performed one and two year ago, presented with four-week left lower quadrant abdominal pain. Computed
tomography and magnetic resonance imaging revealed a solid aggressive osteolytic mass of the left iliac bone with
extensive soft tissue invasion. Biopsy of the tumor was performed and showed a sarcomatous proliferation
consistent with metastatic malignant phyllodes tumor. The patient received the same chemotherapy regimen as in
the first case but without any response on her imaging follow up after 6 months.
Conclusion: Malignant phyllodes tumor is a rare and aggressive fibroepithelial neoplasm. An accurate diagnosis of
metastases should be based on clinicopathological correlation allowing exclusion of differential diagnoses. The goal
of successful managing this tumor is early detection and complete resection prior to dissemination.
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Background
Phyllodes tumors (PTs) are rare fibroepithelial tumors ac-
counting for less than 1 % of all breast neoplasms [1, 2].
They are classified as benign, borderline and malignant [3].
Malignant PTs account for 20 % of all PTs [4] and may
present with delayed metastases mainly in the lung [5].
Only a few cases of PT metastatic to bone have been
reported [6]. To our knowledge, only 2 cases involving
the iliac bone [6, 7] and 1 case involving the femur [8]
are described in the literature. These papers have mainly
focused on their radiological aspects. We report 2 cases
of metastatic malignant PT of the breast involving the
femoral head and the iliac bone and discuss the histo-
pathological differential diagnoses.
Case presentation
Case 1: Clinical history
A 40 year-old white woman presented with a three-week
history of pain and functional impairment of the left lower
limb. Clinical examination showed limitation of the left
lower limb movements. Her clinical past was remarkable
for previous left mastectomy and for malignant PT per-
formed one year ago. The mass measured 7x5x4 cm.
Histological examination showed a biphasic proliferation
characterized by a double layered epithelial component ar-
ranged in clefts surrounded by an hpercellular
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fibrosarcomatous component organized in leaf-like struc-
tures Fig. 1. There was stromal overgrowth, marked nu-
clear atypia and high mitotic activity (12 per 10 high-
power fields). Surgical margins were complete and of at
least 1 cm. Immunoreactivity with anti vimentin was
found. Smooth muscle actin, desmin, CD34, S-100 pro-
tein, CD10, CKAE1/AE3, P63, estrogen and progesterone
receptors were negative. Post operatively, the patient re-
ceived radiation to the tumor bed at a dose of 50 Grays in
25 fractions without chemotherapy.
Radiologic and histopathologic findings
Computed tomography and FDG-PET Scan revealed a
moth-eaten appearance Fig. 2 and pathological FDG up-
take of the left femoral head without other suspect
lesions. The patient underwent computed guided fem-
oral head biopsy. The post-operative course was un-
eventful. Microscopic examination showed a
proliferation of fascicles of spindle cells with nuclear aty-
pia and numerous mitotic figures Figs. 3 and 4. No areas
of epithelial, osteoid or chondroid components were
identified. Immunohistochemistry demonstrated only
vimentin positivity. Pancytokeratin, smooth muscle
actin, desmin, S100 protein, CD34, CD31, CD99, CD117,
estrogen and progesterone receptors were all negative.
Thus, a diagnosis of metastatic
malignant PT was made. The patient received ifosfa-
mide and adriamycin chemotherapy. She is doing well
without any evidence of progression on her imaging
follow-up after 8 months.
Case 2: Clinical history
A 48 year-old white woman presented with a four-week
history of left lower quadrant abdominal pain. The pa-
tient’s past medical history was significant for previous
bilateral mastectomy for malignant PT one and two year
ago Fig. 5. The tumors measured 10x8x5 cm in the right
breast (first mastectomy) and 6×5×4,5 cm in the left
breast. They showed stromal overgrowth, marked nu-
clear atypia and high mitotic activity (greater than 14
per 10 high-power fields). Surgical margins were
complete and of at least 0,7 cm on the right breast and
1,2 cm on the left breast. Immunoreactivity was found
only with vimentin and CD10. The patient received radi-
ation only to the right tumor bed at a dose of 50 Grays
in 25 fractions without chemotherapy.
Radiologic and histopathologic findings
Computed tomography and magnetic resonance imaging
revealed a solid aggressive osteolytic mass of the left iliac
bone with extensive soft tissue invasion measuring 13 ×
Fig. 1 Malignant PT of the breast showing a leaf-like pattern with
increased stromal cellularity and atypia (hematoxylin and eosin stain,
original magnification × 100)
Fig. 2 Axial computed tomography image showing a moth-eaten
appearance of the femoral head
Fig. 3 Fascicular proliferation of spindle shaped cells (hematoxylin
and eosin stain, original magnification × 100)
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11 cm Fig. 6. Biopsy of the tumor was performed and
showed a sarcomatous proliferation similar to that de-
scribed for the first case Figs. 7 and 8 with the same im-
munohistochemical profile. A diagnosis of metastatic
malignant PT of the breast was made. The patient re-
ceived the same chemotherapy regimen as in the first
case but without any response after 7 months. The on-
cologist decided to use taxanes as second line chemo-
therapy with radiological stabilization on her imaging
follow up.
Discussion
PT is a rare fibroepithelial tumor accounting for less
than 1 % of all breast neoplasms [1, 2]. They usually
arise in women between ages 35 and 55 years and are
classified as benign, borderline and malignant [2, 3].
Malignant types present approximately 20 % of all cases
[4]. Actually, malignant PTs should be treated by conser-
vative surgery with adequate negative surgical margins;
the use of radiotherapy may be limited to patients with
positive surgical margins [9, 10]. Distant metastases are
seen in 10–20 % of cases [1]. They can occur even after
technically adequate initial breast surgery [1]. The most
reliable predictive factors for development of distant me-
tastases are stromal overgrowth, nuclear pleomorphism
and high mitotic activity [9, 11], whereas the role of
tumor size and local recurrence is controversial [1, 11,
12]. Tan et al. found, by multivariate analysis, that stro-
mal atypia, overgrowth, surgical margins and mitoses are
independently predictive of clinical behaviour [13]. He
developed a nomogram based on these criteria to predict
recurrence-free survival, but the amalgamation of local
Fig. 4 Tumor cells showing mild nuclear atypia (hematoxylin and
eosin stain, original magnification × 400)
Fig. 5 Malignant PT of the breast showing a periductal stromal
growth with malignant features (hematoxylin and eosin stain,
original magnification × 100)
Fig. 6 Axial computed tomography showing a solid aggressive
osteolytic mass of the left iliac bone with extensive soft
tissue invasion
Fig. 7 Proliferation of densely packed spindle cells (hematoxylin and
eosin stain, original magnification × 100)
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with distant recurrences and the low rate of metastasis
in this series could limit its ability in predicting dissem-
ination. The recurrence free survival was 0,8 and 0,47 at
1 and 3 years for the first case, 0,76 and 0,4 at 1 and
3 years for the second case. Al-Masry et al. have shown
that the expression of CD10 can be used to predict the
occurrence of distant metastasis [14].
Metastatic PTs mainly develop from 3 to 10 years after
the inital therapy, but they can be delayed or occur as
soon as synchronous presentation [11]. The lung is the
most common site of metastatic spread [2, 3, 15]. Only a
few cases of PT metastatic to bone have been reported
[6] with 2 cases involving the iliac bone [6, 7] and 1 case
involving the femur [8].
Clinical features are not specific and vary among loca-
tion of bone metastasis. Radiographs and computed
tomography may show a solid mass adjacent to the in-
volved bone and infiltrating the cortex and medulla in a
permeative pattern [8]. The magnetic resonance imaging
may better delineate the metastatic extent [8].
Pathological examination shows a malignant proliferation
of fascicles of spindle cells with nuclear atypia and high mi-
totic index without epithelial component [15, 16].
Immunohistochemistry demonstrates only vimentin
positivity. Pancytokeratin, smooth muscle actin, desmin,
S100 protein, CD34, C31, CD99 and CD117 are gener-
ally negative [15, 16].
Positivity of estrogen and progesterone receptors had
never been reported. These morphological and immuno-
histochemical findings play an important role in exclud-
ing sarcomas, myoepithelioma, metastatic sarcomatoid
carcinoma, melanoma and gastrointestinal stromal
tumor. Generally, it’s difficult to make a specific diagno-
sis only by microscopic examination, but the final diag-
nosis should be based on clinicopathological correlation.
There is no consensus regarding adjuvant therapy. Both
radiotherapy and chemotherapy are recommended in
metastatic PTs [2, 6, 16]. Ifosfamide is the most active
agent [16]; antiestrogen therapy is not indicated [3, 16].
Some studies revealed several potentially targetable path-
way including epidermal growth factor receptor, angiogen-
esis (vascular endothelial growth factor A, angiopoietin-2,
vascular cell adhesion molecule 1, platelet- derived growth
factor receptor A, pituitary tumor-transforming1) and im-
munotherapy (programmed cell death protein 1, pro-
grammed death-ligand 1) for patients with locally
advanced or metastatic tumors [4, 10]. Park et al. reported
a major response to sunitinib and paclitaxel in a case of
lung metastatic malignant PT of breast [17].
Little is known about the prognosis of bone metastasis
from malignant PT. Nguyen [6] report one case involv-
ing the left iliac bone with good response after radio-
therapy. The prognosis of malignant PT metastatic to
the lung seems to be worse [2].
Conclusion
In summary, malignant PT is a rare and aggressive
fibroepithelial neoplasm. An accurate diagnosis of me-
tastases should be based on clinicopathological correl-
ation allowing exclusion of differential diagnoses. The
goal of successful managing this tumor is early detection
and complete resection prior to dissemination.
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Fig. 8 Tumor cells showing severe nuclear atypia with mitoses
(hematoxylin and eosin stain, original magnification × 400)
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